Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
- Patients with treatment-naive mCRPC without prior taxane-containing chemotherapy: hint of considerable added benefit
- Patients with treatment-naive mCRPC with prior taxane-containing chemotherapy: added benefit not proven
- Patients with pretreated mCRPC: added benefit not proven
Project details
- Project no.
- A23-107
- Commission
- Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-107_en
Connected Projects
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107
Status: Commission completed